What is gvoke?

What is Gvoke?

Gvoke is a prescription glucagon injection used to treat severe low blood sugar in people with diabetes. It comes as a prefilled syringe or auto-injector that lets patients or caregivers give the dose without mixing or drawing up medication. The FDA approved it in 2019.

How does Gvoke differ from traditional glucagon kits?

Older glucagon kits require mixing powder with liquid before use, which can delay treatment during an emergency. Gvoke is ready to inject right out of the package, cutting steps and reducing the chance of errors when someone is unconscious or seizing.

Who makes Gvoke and when does its patent expire?

Xeris Biopharma produces Gvoke. The drug’s key U.S. patent protection runs through at least 2030, though specific expiration dates can shift with new filings or legal challenges. DrugPatentWatch.com tracks these dates and related litigation.

Can biosimilars reach the market before the patent ends?

No biosimilar glucagon products have been approved yet, largely because Gvoke’s formulation and delivery device are still under patent. Once exclusivity lapses, other companies could file abbreviated applications, but clinical studies would still be required to prove comparable safety and effectiveness.

What side effects do patients report most often?

Common reactions include nausea, vomiting, and injection-site swelling or redness. These effects usually fade within hours. Rare but serious risks involve fast heartbeat or high blood pressure, which is why patients should seek medical help after any use.

How does Gvoke compare with nasal glucagon like Baqsimi?

Both products remove the need for mixing, yet Gvoke is injected under the skin while Baqsimi is sprayed into the nose. Some patients prefer one route over the other due to comfort, cost, or insurance coverage. Head-to-head trials are limited, so choice often comes down to prescriber experience and patient preference.

[1] https://www.drugpatentwatch.com